DBV Technologies names Lucia Septien chief medical officer
Dr. Septién has more than 20 years of experience in the pharmaceutical industry, where she has a strong track record in drug development and medical affairs.
She has held several senior positions, leading R&D and Portfolio Management Strategy teams in a wide range of therapeutic areas, including small molecules and biologicals.
Dr. Septién spent most of her career at Pfizer and Wyeth. At Pfizer, she served as Vice President of the Specialty Care Business Unit, Europe, where she led a team of over 300 staff providing medical and scientific support in several therapeutic areas, including immunology, vaccines, inflammation, and rare diseases.
Prior to Pfizer, Dr. Septién served at Wyeth Pharma as Assistant Vice President, Global Neuroscience, responsible for major Phase II and III development programs, including the clinical studies of monoclonal antibodies in Alzheimer's disease in over 27 countries.
She also contributed to several product registrations with both the U.S. Food and Drug Administration and the European Medicines Agency.
Prior to joining DBV, Dr. Septién was Vice President, Global Neurosciences, responsible for the Medical Strategy of the Botulinum Toxin portfolio at Ipsen.
She earned her medical degree and specialized in Psychiatry at the National University of Mexico City. She completed her post-graduate training in Nuclear Medicine at the Commisariat de l'Energie Atomique in Saclay, France. ■
LATEST MOVES FROM France
- CEO Eric Olsen to leave LafargeHolcim after Syria investigation
- Ipsen appoints Alexandre Lebeaut as EVP
- Former French President Nicolas Sarkozy joins Accor board
- Pixium Vision appoints Didier Laurens as CFO
- Nicolas Dufourcq appointed to Orange board of directors
More inside POST
Renren Q4 revenues jump nearly 50% Earnings